Vanguard Group
VOR icon

Vanguard Group’s Vor Biopharma VOR Stock Holding History

Vanguard Group’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$10.1M Buy
770,250
+665,060
+632% +$12.4M ﹤0.01% 2963
2025
Q3 		$5.12M Buy
105,190
+9,410
+10% +$378K ﹤0.01% 3276
2025
Q2 		$3.1M Sell
95,780
-1,231
-1% -$10.9K ﹤0.01% 3376
2025
Q1 		$1.39M Sell
97,011
-130
-0.1% -$3.12K ﹤0.01% 3606
2024
Q4 		$2.16M Sell
97,141
-573
-0.6% -$9.5K ﹤0.01% 3544
2024
Q3 		$1.37M Hold
97,714
– – ﹤0.01% 3675
2024
Q2 		$1.95M Buy
97,714
+7,069
+8% +$229K ﹤0.01% 3558
2024
Q1 		$4.3M Buy
90,645
+3,472
+4% +$152K ﹤0.01% 3354
2023
Q4 		$3.92M Buy
87,173
+1,351
+2% +$55.8K ﹤0.01% 3379
2023
Q3 		$3.64M Buy
85,822
+198
+0.2% +$10.7K ﹤0.01% 3378
2023
Q2 		$5.29M Buy
85,624
+6,659
+8% +$608K ﹤0.01% 3268
2023
Q1 		$8.5M Buy
78,965
+19,398
+33% +$2.15M ﹤0.01% 3022
2022
Q4 		$7.92M Buy
59,567
+26,710
+81% +$2.64M ﹤0.01% 3059
2022
Q3 		$2.62M Hold
32,857
– – ﹤0.01% 3633
2022
Q2 		$3.27M Sell
32,857
-165
-0.5% -$16.9K ﹤0.01% 3584
2022
Q1 		$3.99M Sell
33,022
-14,584
-31% -$2.48M ﹤0.01% 3636
2021
Q4 		$11.1M Sell
47,606
-17,447
-27% -$5.03M ﹤0.01% 3152
2021
Q3 		$20.4M Buy
65,053
+22,884
+54% +$6.8M ﹤0.01% 2855
2021
Q2 		$15.7M Buy
42,169
+1,841
+5% +$908K ﹤0.01% 2960
2021
Q1 		$34.8M Buy
+40,328
New +$34.1M ﹤0.01% 2503

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group's VOR Position: Q4 2025 in Review

Vanguard Group increased its Vor Biopharma (VOR) stake by 632% in Q4 2025, buying an estimated $12.4M and bringing the position to 770,250 shares worth $10.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2963.

Vanguard Group first reported a position in VOR in Q1 2021 and has held it in 20 quarters since. The position peaked at $34.8M in Q1 2021. 55 funds tracked by Wall St. Rank hold VOR as of Q4 2025.

  • Vanguard Group held 770,250 shares of Vor Biopharma worth $10.1M as of Q4 2025.
  • Vanguard Group bought 665,060 Vor Biopharma shares in Q4 2025, an estimated $12.4M.
  • Vor Biopharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2963 holding.
  • Vanguard Group first reported a position in Vor Biopharma in Q1 2021 and has held it in 20 quarters since.
  • Vanguard Group's Vor Biopharma position peaked at $34.8M in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.